PPA
MRTX

Parametric Portfolio Associates’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Parametric Portfolio Associates’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$4.57M Buy
55,537
+28,561
+106% +$2.92M ﹤0.01% 1913
2021
Q4 		$3.96M Sell
26,976
-22,606
-46% -$3.51M ﹤0.01% 2024
2021
Q3 		$8.77M Buy
49,582
+21,063
+74% +$3.39M 0.01% 1456
2021
Q2 		$4.61M Buy
28,519
+682
+2% +$110K ﹤0.01% 1897
2021
Q1 		$4.77M Sell
27,837
-9,354
-25% -$1.85M ﹤0.01% 2209
2020
Q4 		$8.17M Buy
37,191
+9,736
+35% +$2.1M 0.01% 1730
2020
Q3 		$4.56M Buy
27,455
+12,538
+84% +$1.72M ﹤0.01% 1962
2020
Q2 		$1.7M Buy
14,917
+5,029
+51% +$488K ﹤0.01% 2593
2020
Q1 		$760K Sell
9,888
-4,719
-32% -$423K ﹤0.01% 2952
2019
Q4 		$1.88M Sell
14,607
-1,085
-7% -$105K ﹤0.01% 2729
2019
Q3 		$1.22M Sell
15,692
-2,057
-12% -$193K ﹤0.01% 2925
2019
Q2 		$1.83M Buy
17,749
+4,435
+33% +$345K ﹤0.01% 2724
2019
Q1 		$976K Buy
+13,314
New +$906K ﹤0.01% 3041
2018
Q4 		– Sell
-19,623
Closed -$924K – 3975
2018
Q3 		$924K Sell
19,623
-11,888
-38% -$662K ﹤0.01% 3144
2018
Q2 		$1.55M Buy
+31,511
New +$1.19M ﹤0.01% 2831

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Parametric Portfolio Associates's MRTX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 106% in Q1 2022, buying an estimated $2.92M and bringing the position to 55,537 shares worth $4.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

Parametric Portfolio Associates first reported a position in MRTX in Q2 2018 and has held it in 15 quarters since. The position peaked at $8.77M in Q3 2021. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • Parametric Portfolio Associates held 55,537 shares of Mirati Therapeutics, Inc. Common Stock worth $4.57M as of Q1 2022.
  • Parametric Portfolio Associates bought 28,561 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $2.92M.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1913 holding.
  • Parametric Portfolio Associates first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and has held it in 15 quarters since.
  • Parametric Portfolio Associates's Mirati Therapeutics, Inc. Common Stock position peaked at $8.77M in Q3 2021.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.